TrialClinical pharmacokinetics2018

Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.

Kevinkumar A Kansagra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.